RxDoctor Payments Data

Sara Johnson

Nurse Practitioner · Knoxville, TNNPI 1720679434

Payments from drug & device makers

$6,824in general payments, 2019–2025

Across 367 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Novartis$700
  • Pfizer$668
  • Cvrx, Inc.$517
  • Amgen$512
  • Bayer$459
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$6,797100%
  • Education$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,824 in reported general payments places this provider in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$103,884
Medicare patients
509
Services billed
1,701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban313$308,046
XareltoRivaroxaban84$89,593
EntrestoSacubitril/Valsartan53$41,315
MultaqDronedarone Hcl31$28,613
Dofetilide199$17,857
Flecainide Acetate269$10,115
Dabigatran EtexilateDabigatran Etexilate Mesylate34$7,081
Metoprolol Succinate290$4,160
SotalolSotalol Hcl266$3,746
Amiodarone Hcl114$1,371
Diltiazem 24hr Er (Cd)Diltiazem Hcl52$1,004
Mexiletine Hcl21$914
ClopidogrelClopidogrel Bisulfate101$753
Potassium Chloride50$628
Spironolactone70$340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$668$308,046313 claims
Johnson & JohnsonXarelto$198$89,59384 claims
NovartisEntresto$700$41,31553 claims
Sanofi-aventis U.S. LLCMultaq$61$28,61331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →